Skip to main content
Top
Published in: Journal of Clinical Immunology 6/2013

01-08-2013 | Key Review Article

The Spread of the J Project

Authors: Zsuzsa Horváth, Nima Rezaei, Ismail Reisli, Irina Tuzankina, Nurzhan Otarbayev, Panteley Popandopulo, László Maródi

Published in: Journal of Clinical Immunology | Issue 6/2013

Login to get access

Abstract

The J Project physician education and clinical research collaboration program was launched in 2004 in Eastern and Central Europe (ECE). In less than 10 years, it has achieved remarkable success. This project aims to increase knowledge in the field of primary immunodeficiency disorders (PID), and to improve the diagnosis and treatment of patients worldwide, particularly in countries with limited economic resources, which currently report fewer such patients than expected. In most ECE countries, gene sequencing, which can provide a definitive diagnosis of PID, still remains unavailable. By contrast, such technology is used elsewhere to detect the more than 200 PID-causing genes that have been discovered in the last three decades. Thus, PID awareness programs like the J Project remain critically important, to improve diagnostic facilities and treatment and to promote clinical research collaboration. This paper highlights the achievements of the J Project and the spread of its concepts and spirit to the countries of Western Asia.
Literature
1.
go back to reference Maródi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol. 2007;7:851–61.PubMedCrossRef Maródi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol. 2007;7:851–61.PubMedCrossRef
2.
go back to reference Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. 2007;317:617–9.PubMedCrossRef Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. 2007;317:617–9.PubMedCrossRef
4.
go back to reference Maródi L. The creation and progress of the J Project in Eastern and Central Europe. Ann NY Acad Sci. 2011;1238:65–73.PubMedCrossRef Maródi L. The creation and progress of the J Project in Eastern and Central Europe. Ann NY Acad Sci. 2011;1238:65–73.PubMedCrossRef
5.
go back to reference Maródi L, Casanova JL. Primary immunodeficiency diseases: the J Project. Lancet. 2009;373:2179–81.PubMedCrossRef Maródi L, Casanova JL. Primary immunodeficiency diseases: the J Project. Lancet. 2009;373:2179–81.PubMedCrossRef
6.
go back to reference Maródi L, Notarangelo LD. Education and worldwide collaboration pays off. Nat Immunol. 2007;8:323–4.PubMedCrossRef Maródi L, Notarangelo LD. Education and worldwide collaboration pays off. Nat Immunol. 2007;8:323–4.PubMedCrossRef
7.
go back to reference Tóth B, Volokha A, Mihas A, Pac M, Bernatowska E, Kondratenko I, et al. Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol. 2009;46:2140–6.PubMedCrossRef Tóth B, Volokha A, Mihas A, Pac M, Bernatowska E, Kondratenko I, et al. Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol. 2009;46:2140–6.PubMedCrossRef
8.
go back to reference Gulácsy V, Freiberger T, Shcherbina A, Pac M, Chernyshova L, Avcin T, et al. Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome. Mol Immunol. 2011;48:788–92.PubMedCrossRef Gulácsy V, Freiberger T, Shcherbina A, Pac M, Chernyshova L, Avcin T, et al. Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome. Mol Immunol. 2011;48:788–92.PubMedCrossRef
9.
go back to reference Tuzankina I, Kobeleva Y, Kiseleva N, Bolkov M, Reuter G, Maródi L. Cytotoxic T lymphocytes mediate neuronal injury in patients with X-linked agammaglobulinemia and progressive neurodegenerative disease. Allergy. 2011;66:1617–8.PubMedCrossRef Tuzankina I, Kobeleva Y, Kiseleva N, Bolkov M, Reuter G, Maródi L. Cytotoxic T lymphocytes mediate neuronal injury in patients with X-linked agammaglobulinemia and progressive neurodegenerative disease. Allergy. 2011;66:1617–8.PubMedCrossRef
10.
go back to reference Tóth B, Wolff AS, Halász Z, Tar A, Szüts P, Ilyés I, et al. Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy. Clin Endocrinol. 2010;72:641–7.CrossRef Tóth B, Wolff AS, Halász Z, Tar A, Szüts P, Ilyés I, et al. Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy. Clin Endocrinol. 2010;72:641–7.CrossRef
11.
go back to reference Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.PubMedCrossRef Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.PubMedCrossRef
12.
go back to reference Sanal O, Tezcan I. Thirty years of primary immunodeficiencies in Turkey. Ann NY Acad Sci. 2011;1238:15–23.PubMedCrossRef Sanal O, Tezcan I. Thirty years of primary immunodeficiencies in Turkey. Ann NY Acad Sci. 2011;1238:15–23.PubMedCrossRef
13.
go back to reference Azarsiz E, Gulez N, Edeer KN, Aksu G, Kutukculer N. Consanguinity rate and delay in diagnosis in Turkish patients with combined immunodeficiencies: a single centre study. J Clin Immunol. 2011;31:106–11.PubMedCrossRef Azarsiz E, Gulez N, Edeer KN, Aksu G, Kutukculer N. Consanguinity rate and delay in diagnosis in Turkish patients with combined immunodeficiencies: a single centre study. J Clin Immunol. 2011;31:106–11.PubMedCrossRef
14.
go back to reference Yorulmaz A, Artaç H, Kara R, Keleş S, Reisli İ. Retrospective evaluation of 1054 patients with primary immunodeficiency (in Turkish). Allergy Asthma Immunol. 2008;6:127–34. Yorulmaz A, Artaç H, Kara R, Keleş S, Reisli İ. Retrospective evaluation of 1054 patients with primary immunodeficiency (in Turkish). Allergy Asthma Immunol. 2008;6:127–34.
15.
go back to reference CEREDIH: The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135:264–72.CrossRef CEREDIH: The French PID study group. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135:264–72.CrossRef
16.
go back to reference Rezaei N, Mohammadinejad P, Aghamohammadi A. The demographics of primary immunodeficiency diseases across the unique ethnic groups in Iran, and approaches to diagnosis and treatment. Ann N Y Acad Sci. 2011;1238:24–32.PubMedCrossRef Rezaei N, Mohammadinejad P, Aghamohammadi A. The demographics of primary immunodeficiency diseases across the unique ethnic groups in Iran, and approaches to diagnosis and treatment. Ann N Y Acad Sci. 2011;1238:24–32.PubMedCrossRef
17.
go back to reference Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in Iran. Iran J Pediatr. 2010;20:16–34.PubMed Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in Iran. Iran J Pediatr. 2010;20:16–34.PubMed
18.
go back to reference Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26:519–32.PubMedCrossRef Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26:519–32.PubMedCrossRef
19.
go back to reference Rezaei N, Aghamohammadi A, Notarangelo LD. Primary immunodeficiency diseases: Definition, diagnosis and management. Berlin Heidelberg: Springer; 2008.CrossRef Rezaei N, Aghamohammadi A, Notarangelo LD. Primary immunodeficiency diseases: Definition, diagnosis and management. Berlin Heidelberg: Springer; 2008.CrossRef
20.
go back to reference Nourijelyani K, Aghamohammadi A, Salehi SM, Behniafard N, Abolhassani H, Pourjabar S, et al. Physicians’ awareness on primary immunodeficiency disorders in Iran. Iran J Allergy Asthma Immunol. 2012;11:57–64.PubMed Nourijelyani K, Aghamohammadi A, Salehi SM, Behniafard N, Abolhassani H, Pourjabar S, et al. Physicians’ awareness on primary immunodeficiency disorders in Iran. Iran J Allergy Asthma Immunol. 2012;11:57–64.PubMed
21.
go back to reference Mahdaviani SA, Hirbod-Mobarakeh A, Wang N, Aghamohammadi A, Hammarström L, Masjedi MR, et al. Novel mutation of the activation-induced cytidine deaminase gene in a Tajik family: special review on hyper-immunoglobulin M syndrome. Expert Rev Clin Immunol. 2012;8:539–46.PubMedCrossRef Mahdaviani SA, Hirbod-Mobarakeh A, Wang N, Aghamohammadi A, Hammarström L, Masjedi MR, et al. Novel mutation of the activation-induced cytidine deaminase gene in a Tajik family: special review on hyper-immunoglobulin M syndrome. Expert Rev Clin Immunol. 2012;8:539–46.PubMedCrossRef
Metadata
Title
The Spread of the J Project
Authors
Zsuzsa Horváth
Nima Rezaei
Ismail Reisli
Irina Tuzankina
Nurzhan Otarbayev
Panteley Popandopulo
László Maródi
Publication date
01-08-2013
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 6/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-013-9905-2

Other articles of this Issue 6/2013

Journal of Clinical Immunology 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine